Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Description

Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.

Conditions

Intrahepatic Cholangiocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Condition
Intrahepatic Cholangiocarcinoma
Intervention / Treatment

-

Contacts and Locations

Baltimore

The Johns Hopkins Hospital, Baltimore, Maryland, United States, 10017

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients \>18 years of age and ≤80 years of age;
  • * Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as intrahepatic cholangiocarcinoma; preoperative imaging assessment is resectable;
  • * No obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy
  • * Liver function Child-Turcotte-Pugh score A-B grade;
  • * Residual liver volume \>30%; can tolerate radical hepatectomy
  • * The patient has autonomy, understands and voluntarily signs the written informed consent and is able to complete the follow-up plan;
  • * Sign the written informed consent form prior to the test screening.
  • * The patient has obvious heart, lung, brain and kidney dysfunction that affects the treatment of intrahepatic cholangiocarcinoma;
  • * The patient has a history of other malignant tumors;
  • * Liver function Child-Turcotte-Pugh score C;
  • * The investigator determined that it was not suitable for the study.

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Second Affiliated Hospital, School of Medicine, Zhejiang University,

Study Record Dates

2027-12-31